• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    2seventy bio, Inc. - Common Stock (NQ: TSVT )

    4.380 -0.190 (-4.16%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 167,285
    Open 4.530
    Bid (Size) 4.300 (3)
    Ask (Size) 4.400 (1)
    Prev. Close 4.570
    Today's Range 4.350 - 4.750
    52wk Range 1.535 - 10.02
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Hidden Stock Gems That Wall Street Is Overlooking
    If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three. 
    Via InvestorPlace
    Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
    2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
    Via Benzinga

    Performance

    YTD
    +6.83%
    +6.83%
    1 Month
    +13.47%
    +13.47%
    3 Month
    +2.58%
    +2.58%
    6 Month
    +41.75%
    +41.75%
    1 Year
    -55.40%
    -55.40%

    More News

    Read More
    2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Participate in Upcoming Investor Conferences
    From 2seventy bio, Inc.
    Via Business Wire
    A Preview Of 2seventy bio's Earnings
    Via Benzinga
    TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
    From 2seventy bio, Inc.
    Via Business Wire
    FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
    Via Benzinga
    Exposures Product Safety
    FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
    Via Benzinga
    Exposures Product Safety
    U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
    From Bristol Myers Squibb
    Via Business Wire
    2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
    From 2seventy bio, Inc.
    Via Business Wire
    Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
    From Bristol Myers Squibb
    Via Business Wire
    Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
    Via Benzinga
    TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
    From 2seventy bio, Inc.
    Via Business Wire
    Earnings Scheduled For March 5, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.